GlassScriptPhysician profile
Edwin Figueroa
NPI 1871119396
$1,750.26
in general payments reported to CMS, 2019-2025
21 companies · $35.82 in 2025
The $35.82 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $509 · 2023: $78.19 · 2024: $208 · 2025: $35.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $419.41 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.70 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $244.30 | 2021-2024 | Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $133.04 | 2021-2023 | Shingrix |
| Lilly USA, LLC | $92.86 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.41 | 2021-2022 | |
| Pfizer INC. | $67.47 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.19 | 2021-2022 | |
| Phadia US INC. | $55.68 | 2021-2025 | Immunocap |
| Abbvie INC. | $50.67 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.28 | 2021-2022 | |
| Genentech USA, INC. | $33.10 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $31.33 | 2021-2022 | |
| Boston Scientific Corporation | $29.04 | 2021 | |
| Sanofi Pasteur INC. | $26.43 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $19.11 | 2021 | |
| Cranial Technologies, INC | $18.41 | 2023 | Doc Band |
| Exact Sciences Corporation | $14.72 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $14.02 | 2021 | |
| Amgen INC. | $13.36 | 2024 | Repatha, Otezla |
| Shield Therapeutics INC | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Figueroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.